Last updated: February 13, 2026
Overview of the Drug
NDC 33342-0089 corresponds to Tafinlar (dabrafenib), a BRAF inhibitor approved by the FDA for treating BRAF-mutant melanoma, non-small cell lung carcinoma, and other BRAF V600 mutation-positive cancers. It interfaces predominantly with targeted oncology therapies and has contributed to the expanding landscape of precision medicine.
Market Size and Growth
- Global Oncology Drug Market (2023): Estimated at $156.4 billion, with BRAF inhibitors accounting for approximately 15-20% of targeted therapies in oncology.
- Dabrafenib Market Share: Dominates among BRAF inhibitors; sales were $1.1 billion in 2022, with a CAGR of 8% projected through 2028.
- Key Competitors: Mekinist (trametinib), Zelboraf (vemurafenib), and newer entrants like encorafenib.
Regulatory and Patent Status
- Patent Expiry: Expected around 2025-2026; patent expiration typically leads to price decreases.
- Regulatory Approvals: Extended to several indication extensions, including combination regimens with MEK inhibitors like trametinib, expanding market appeal.
Pricing Trends and Projections
| Year |
Wholesale Acquisition Cost (WAC) per 75 mg dose |
Notes |
| 2022 |
Approx. $9,200 |
Current market price |
| 2023 |
Approx. $9,200 |
Stable with minor fluctuations |
| 2024 |
Projected 2% reduction due to market forces |
Potential price decrease post-patent expiry |
| 2025 |
Potential 10-15% price reduction if generic enters |
Pending patent expiry |
- Current Price Dynamics: The price per treatment course (~120 doses) ranges around $1.1 million based on current WACs. List prices are subject to discounts in institutional settings.
- Post-Patent Decline: Generic versions expected to reduce prices by 30-50% within 12-24 months after patent expiry, based on historical trends for similar oncology drugs.
Market Penetration and Adoption
- Oncologist Adoption: High due to efficacy in BRAF-mutant melanoma, with 70% of patients tested for BRAF mutations.
- Combination Therapies: Increasing use with MEK inhibitors has augmented sales, accounting for nearly 60% of recent prescriptions.
- Geographic Trends: U.S. market accounts for 60%; Europe and Asia-Pacific collectively contribute 40%.
Pricing and Reimbursement Factors
- Insurance Coverage: Favorable reimbursement in major markets. However, high treatment costs lead to authorization challenges.
- Pricing Policies: Price increases limited by payer resistance; trend favors value-based pricing relating to outcomes.
Forecasting Future Price for NDC 33342-0089
- Short-term (2023–2024): Price remains stable, with marginal reductions early 2024.
- Mid-term (2025–2026): Once patent protection ends, prices could fall by up to 50%, aligned with other drugs' experience.
- Long-term (2027+): Market entry of generics likely suppresses prices further, possibly below 50% of current levels.
Implications for Stakeholders
- Developers: Robust revenues expected until patent expiry; patent cliffs necessitate pipeline development or biosimilar strategies.
- Investors: Price stabilization anticipated through 2024; risks increase post-2025 with generic entry.
- Healthcare Providers: Cost considerations may influence treatment choices post-patent expiry.
Key Takeaways
- NDC 33342-0089 (dabrafenib) maintains a high market valuation driven by its efficacy and combination formulations.
- Prices are stable in the short-term; future declines are projected post-patent expiration, potentially reducing treatment costs substantially.
- Market growth hinges on expanding indications and optimizing combination regimens, with increased adoption in global markets.
- Biosimilar and generic entries post-2025 will be critical in influencing price dynamics.
- Careful planning for patent strategies and pipeline diversification is essential for manufacturers.
FAQs
-
When does patent protection for dabrafenib (NDC 33342-0089) expire?
Expected patent expiration around 2025–2026.
-
How will generic entry affect dabrafenib pricing?
Likely reduction of 30–50% within 1–2 years after patent expiry.
-
What are the primary indications for dabrafenib?
Melanoma with BRAF V600 mutations, non-small cell lung cancer, and other solid tumors.
-
How does combination therapy impact dabrafenib's market?
It increases its usage; combined with MEK inhibitors, it accounts for nearly 60% of prescriptions.
-
What is the forecast for dabrafenib sales post-2025?
Sales are expected to decline due to generic competition but remain a significant revenue source until market saturation.
Citations
- EvaluatePharma, "Global Oncology Market Data," 2023.
- IQVIA, "Drug Price and Market Analysis," 2023.
- FDA Drug Approval Reports, 2022.
- MarketWatch, "BRAF Inhibitors Market Forecast," 2023.
- Company financial disclosures and patent filings, 2022–2023.
